Ferrosoferric Oxide clinical trials
Also written Ferumoxytol and Feraheme.
Includes 2 studies of Ferumoxides.
How each study uses Ferrosoferric Oxide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Ferrosoferric Oxide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Aug 1996 · FERIDEX I.V. · NDA 020416 (FDA, Drugs@FDA; as ferumoxides)
- European Union
- 15 Jun 2012 · Rienso · EMEA/H/C/002215 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
79 studies that test it; most in 2011 (7)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2006 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 4 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 65
AMAG Pharmaceuticals, Inc. (13) · OHSU Knight Cancer Institute (13) · Stanford University (3) · Auerbach Hematology Oncology Associates P C (3) · University of Pennsylvania (3) · Brigham and Women's Hospital (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2)
Often tested with
Tested in the same studies.
Ferrous sulfate (3) · Gadolinium (3) · Temozolomide (1) · Gadofosveset trisodium (1) · Hydrogen Peroxide (1) · Saline Solution (1) · Sodium Chloride (1) · Ascorbic Acid (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Ferrosoferric Oxide.
- May 2027Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection FractionEarly Phase 1 · University of Florida
- Jun 2027Calculating Wall Shear Stress in Infant Pulmonary VeinsPhase 1 · Children's Hospital of Philadelphia
Studies
Open first, then newest update. How each study uses Ferrosoferric Oxide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 79
- Nanozymes in EndodonticsEnrolling by invitationPhase 4University of PennsylvaniaNCT07518901Written as Nanozyme treatmentHow we know
- Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous SystemRecruitingPhase 2OHSU Knight Cancer InstituteNCT03270059Written as FerumoxytolHow we know
- Calculating Wall Shear Stress in Infant Pulmonary VeinsRecruitingPhase 1Children's Hospital of PhiladelphiaNCT06440408Written as FerumoxytolHow we know
- Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection FractionRecruitingEarly Phase 1University of FloridaNCT07634640Written as Ferumoxytol infusionHow we know
- Enhanced MRI Imaging in Healthy Participants and Participants With EpilepsyRecruitingPhase 2University of AlbertaNCT06483061Written as FerumoxytolHow we know
- A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)RecruitingPhase 3AMAG Pharmaceuticals, Inc.NCT03619850Written as FerumoxytolHow we know
- A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric SubjectsRecruitingPhase 3AMAG Pharmaceuticals, Inc.NCT03893045Written as ferumoxytolHow we know
- Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous DiseasesRecruitingPhase 2Min ZhouNCT07452250Written as Ferumoxytol injectionHow we know
- Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma PatientsRecruitingPhase 3Jonsson Comprehensive Cancer CenterNCT07461948Written as FerumoxytolHow we know
- Virtual Histology of the Bladder Wall for Bladder Cancer StagingRecruitingEarly Phase 1Jodi MaranchieNCT04369560Written as Ferumoxytol intravesical administration (5 mM)How we know
- Early Antenatal Support for Iron Deficiency AnemiaRecruitingPhase 4Thomas Jefferson UniversityNCT04278651Written as FerumoxytolHow we know
- Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical PatientRecruitingPhase 3Auerbach Hematology Oncology Associates P CNCT04268849Written as FerumoxytolHow we know
- IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine BleedingRecruitingPhase 4Thomas Jefferson UniversityNCT04205266Written as FerumoxytolHow we know
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance ImagingCompletedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT02511028Written as FerumoxytolHow we know
- Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With CancerCompletedPhase 1/2Stanford UniversityNCT01542879Written as FerumoxytolHow we know
- Novel Imaging Markers in SPMSCompletedEarly Phase 1University of UtahNCT05357833Written as Ferumoxytol infusionHow we know
- Predicting Stroke Risk in ICAD With Novel MRIWithdrawnPhase 4Northwestern UniversityNCT05515874Written as FerahemeHow we know
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in GlioblastomaActive, not recruitingPhase 1Bryan AllenNCT04900792Written as Ferumoxytol injectionHow we know
- Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency AnemiaCompletedPhase 3Stanford UniversityNCT04253626Written as Ferumoxytol Injection [Feraheme]How we know
- Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)CompletedPhase 2AMAG Pharmaceuticals, Inc.NCT00707876Written as ferumoxytolHow we know
See all 79 studies that test Ferrosoferric Oxide →
Given beside what is tested · 5 — Ferrosoferric Oxide is usual care or a partner of the new treatment
- Feasibility of FMISO in Brain TumorsRecruitingPhase 2OHSU Knight Cancer InstituteNCT03649880Written as FerumoxytolHow we know
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm InfantsRecruitingPhase 2University of WashingtonNCT05340465Written as Ferumoxytol injectionHow we know
- Liposomal Irinotecan and Veliparib in Treating Patients With Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT02631733Written as FerumoxytolHow we know
- Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRICompletedNot applicableDanish Headache CenterNCT02549898Written as FerahemeHow we know
- MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentCompletedPhase 1IpsenNCT01770353Written as FerumoxytolHow we know
Codes
What other systems call Ferrosoferric Oxide · ClinicalTrials.gg INT008874
- MeSH (NLM) D052203Ferrosoferric OxideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) XM0M87F357FERROSOFERRIC OXIDEConfirmed FDA, NLM
- RxNorm 1310708One source FDA
- NCI Thesaurus C38138Ferrosoferric OxideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D052203 | Ferrosoferric Oxide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | XM0M87F357 | FERROSOFERRIC OXIDE | Confirmed FDA, NLM |
| RxNorm | 1310708 | — | One source FDA |
| NCI Thesaurus | C38138 | Ferrosoferric Oxide | One source FDA |
Also registered as ferumoxytol (UNII R8DG7T2D3A) and ferumoxytol non-stoichiometric magnetite (UNII CLH5FT6412 · RxNorm 473387).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.